PreCanMed develops one of the most advanced research technologies in cancer medicine: patient derived tumor organoids which enable personalized cancer treatment. In cooperation with an Italian-Austrian Consortium, the working groups for cell biology and translational oncology at the Medical University Innsbruck investigate the tumor organoid technology. Patient derived tumor organoids are the perfect tools to gain information on the drug sensitivity of tumors from individual patients. This approach allows perfect adjustment of therapeutic strategies to individual patients’ needs.



Personalized Therapies

Throughout the last couple of years the trend in cancer treatment is to abandon expensive and ineffective standard therapy concepts and to focus on approaches which are well adjusted to individual patients’ needs. Decisions about individual therapeutics and treatment strategies are based on the genetic and cellular features of the tumor. This approach not only has beneficial socio-economic consequences in terms of costs and quality of life, but also increases life expectancy and recovery prospects of cancer patients.

Competence platform north and south of the Brenner

Strong competences in various areas of personalized cancer medicine have evolved in this region during the last couple of years. Aiming to build a competence platform, scientific and clinical partners have joined forces by forming a supra-regional consortium. The overall project budget amounts to 1.3 million euros, more than 1 million of which are grants from the ERDF (European Regional Development Fund).

Perfect tools for efficacy assessments of therapeutics

Driven by precision medicine, the relevance of tumor organoids is constantly increasing. Tumor organoids are 3-dimensional cell complexes, gained from tumor samples or biopsies, and cultivated in test tubes. Through optimized technologies they can be quickly cultivated and preserve nearly all of the features from the original tumor. Therefore, they allow genotyping of the tumor and, moreover, the sensitivity of the tumor to specific therapeutics can be assessed. This approach spares patients from side effects caused by medicine which don’t have any beneficial effect for their treatment.

PreCanMed is funded by the EU, the ERDF, and the program Interreg V-A Italy-Austria 2014-2020.

Volume: 1.3 million Euro

Duration: 03/2017 – 02/2021

Project partners:

  • LNCIB Laboratorio Nazionale del Consorzio Interuniversitario delle Biotecnologie Area di Ricerca
  • UNITS Universita degli studi di Triest
  • UNIUD Universita degli studi di Udine
  • ADSI Austrian Drug Screening Institute GmbH
  • MUI Medizinische Universität Innsbruck


Sei kein Gefangener der Vergangenheit:
Internet Explorer ist für unsere Technologie zu alt!
Bitte verwende einen der folgenden Browser!